Moderna Q2 Revenue Misses, Norovirus Vaccine Fails Interim, but Cost Cuts Lift Cash Outlook

summarizeSummary

Moderna reported Q2 revenue of $145M and a net loss of $(0.8)B, while its norovirus vaccine candidate failed a Phase 3 interim analysis. The company improved its 2026 cost outlook and raised its year-end cash forecast, with a key FDA decision on its flu vaccine due August 5.

check_boxKey Events · Earnings and Guidance · MRNA

• Q2 Revenue Misses Expectations

  Revenue of $145 million was flat year-over-year and well below Q1's $389 million, driven by lower COVID vaccine sales in the U.S. and South America.

• Norovirus Vaccine Fails Interim

  mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis; the trial remains blinded and an additional cohort will be enrolled.

• Cost Outlook Improves

  2026 GAAP operating expense outlook reduced by ~$200 million; year-end cash balance now projected at $4.7–5.2 billion, up from prior estimate.

• Flu Vaccine PDUFA on August 5

  FDA decision on mFLUSIVA (mRNA-1010) expected August 5, 2026, following unanimous VRBPAC recommendation — potential fifth approved product.

auto_awesomeAnalysis · MRNA · Life Sciences

Second-quarter revenue of $145 million fell short of the $389 million reported in Q1, underscoring the lumpy nature of COVID vaccine sales. The bigger blow is the Phase 3 interim failure of its norovirus vaccine, mRNA-1403, which missed statistical criteria for early success — a setback for a pipeline that investors were counting on to diversify beyond COVID. On the positive side, management improved its 2026 operating expense outlook by roughly $200 million and raised its year-end cash forecast to $4.7–5.2 billion, signaling tighter cost control. The upcoming August 5 PDUFA date for its flu vaccine, mFLUSIVA, now carries even more weight as a potential fifth approved product.